Philip Morris International Releases First TCFD Report, Recognized as Supplier Engagement Leader by CDP
19.4.2023 11:09:00 EEST | Business Wire | Press release
As Philip Morris International Inc. (PMI) (NYSE: PM) strives to remain at the forefront of a fast-evolving environmental, social, and governance (ESG) reporting landscape, the company today released its first-ever TCFD Report to respond to the implementation guidance of the Task Force on Climate-related Financial Disclosures (TCFD). The report’s findings were informed by a structured Climate Change Risk and Opportunity (CCRO) assessment that PMI conducted in 2022, with guidance from an external expert organization and in line with TCFD’s recommendations, to identify relevant climate-related risks and opportunities.
“Stakeholder expectations of businesses are shifting, and regulatory developments are moving forward at pace,” explained Emmanuel Babeau, Chief Financial Officer. “Companies are expected to demonstrate commendable behavior and transparency, providing trustworthy information on their impacts along the value chain and meeting mandatory reporting requirements in a range of jurisdictions. Accordingly, PMI continues to promote transparency by reporting against the most relevant and widely used sustainability standards.”
“For a business like ours—with a diversified agricultural supply chain that is sensitive to climate change—abrupt climate variations can endanger physical infrastructure and supply chains,” said Scott Coutts, Senior Vice President, Operations. “However, addressing the global challenge of climate change also presents opportunities. To realize these opportunities, PMI, alongside many of our suppliers, is working within a global context which is aiming to stabilize the global temperature rise to below the internationally agreed 1.5°C scenario. We understand the potential impacts of climate change across all areas of our operations, particularly upstream in our supply chain.”
PMI has been a supporter of the TCFD since 2021. In recent years, various elements of the company’s publicly available disclosure—such as its annual Integrated Report, CDP Climate disclosure, or annual report on Form10-K—already aligned with much of TCFD’s recommendations. Building on its CCRO assessment completed in 2022, PMI’s TCFD Report now compiles relevant information in one place and will continue to strengthen the company’s capacity to mitigate climate-related risks.
“We are proud to publish this report, which presents how we are implementing TCFD’s recommendations. It outlines the progress made to date toward our goal of incorporating climate-related risk and opportunity identification and management into our overall business strategy and disclosure efforts,” said Jennifer Motles, Chief Sustainability Officer. “It complements our Low-Carbon Transition Plan, published in 2021, which provides a transparent and detailed view on how we plan to achieve our climate ambitions, measure success, and report on progress, as we adapt our business model to succeed in a net-zero carbon economy.”
PMI’s strategies to Tackle Climate Change and Preserve Nature have been recognized by CDP, a not-for-profit charity that runs a global disclosure system for investors, companies, cities, and regions to manage their environmental impacts. In March 2023 and for the sixth consecutive year, PMI was included in CDP’s Supplier Engagement Leaderboard, distinguishing it as a global leader for engaging with suppliers on climate change and recognizing the effort PMI has put toward decarbonization, a key component in achieving its scope 3 ambitions. Additionally, in December 2022, for the third successive year, CDP awarded PMI the prestigious “Triple A” rating for the company’s performance in tackling climate change, protecting forests, and ensuring water security—placing it among the world’s most pioneering companies in environmental transparency and performance.
Earlier this month, PMI published its fourth annual Integrated Report 2022, which aims to provide an objective description of the company’s business model, strategy, performance, governance, and prospects in relation to its priority economic and ESG topics. To access PMI’s latest reports, as well as additional information on its approach to sustainability, please visit pmi.com/sustainability.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match—a leader in oral nicotine delivery—creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration (FDA) has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General snus as modified risk tobacco products (MRTPs). As of December 31, 2022, PMI’s smoke-free products were available for sale in 73 markets, and PMI estimates that approximately 17.8 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 32% of PMI’s total full-year 2022 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma subsidiary, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005249/en/
Contact information
David Fraser
Philip Morris International
+41 (0)58 242 4500
david.fraser@pmi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 13:45:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we see an opportunity to bring decision-makers closer to insight and reduce the manual effort between data and action," said Rishi Padhi, SVP and Chief Digital and Information
Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 13:18:00 EEST | Press release
Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified protocol and statistical analysis plan. Within this clinically high-risk population, myStage Dx identified two groups with markedly different long-term outcomes. The Low Risk group comprised 23.5% of patie
Zoom Advances Its AI Strategy With a New Unified Context Layer That Helps Turn Meeting Conversations Into Completed Work22.10.2026 13:13:00 EEST | Press release
Today at its annual Zoomtopia customer conference, Zoom Communications, Inc. (NASDAQ: ZM), a leading AI-first platform for human connection, introduced a new Unified Context Layer and several new products with AI-powered capabilities. The new offerings are designed to help businesses transform rich meeting context into meaningful deliverables that help accelerate work outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021498160/en/ Business conversations drive critical decisions and build customer history every day. A customer interaction might start in a meeting, continue by phone, and carry on in chat threads. But when that context is scattered across applications, people, and AI agents lose the thread, and teams spend significant time piecing together what happened, when it happened, and what they should do about it. Zoom’s new Unified Context Layer helps close that gap by linking conversation history with releva
TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 13:01:00 EEST | Press release
TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA AI models and tools to further enhance capabilities across advanced reasoning, autonomous analysis and video intelligence. The integration allows TACTICAAI to draw on NVIDIA’s AI ecosystem while maintaini
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 13:01:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
